Erkut Bahceci

5.5k total citations · 1 hit paper
66 papers, 2.9k citations indexed

About

Erkut Bahceci is a scholar working on Hematology, Genetics and Immunology. According to data from OpenAlex, Erkut Bahceci has authored 66 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Hematology, 29 papers in Genetics and 20 papers in Immunology. Recurrent topics in Erkut Bahceci's work include Chronic Myeloid Leukemia Treatments (32 papers), Acute Myeloid Leukemia Research (26 papers) and Chronic Lymphocytic Leukemia Research (25 papers). Erkut Bahceci is often cited by papers focused on Chronic Myeloid Leukemia Treatments (32 papers), Acute Myeloid Leukemia Research (26 papers) and Chronic Lymphocytic Leukemia Research (25 papers). Erkut Bahceci collaborates with scholars based in United States, Japan and Germany. Erkut Bahceci's co-authors include Emmanuel Clave, Susan F. Leitman, A. John Barrett, Nathalie Contentin, Cynthia E. Dunbar, Diane E. Epperson, Neal S. Young, Richard Childs, Elizabeth J. Read and W. Marston Linehan and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Erkut Bahceci

66 papers receiving 2.8k citations

Hit Papers

1 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell Transplantation

2000 770 citations Nathalie Contentin, Erkut Bahceci et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Erkut Bahceci United States	23	1.9k	916	796	766	640	66	2.9k
Nathalie Contentin France	20	2.0k 1.0×	767 0.8×	831 1.0×	520 0.7×	610 1.0×	49	2.8k
Camille N. Abboud United States	27	1.6k 0.8×	558 0.6×	783 1.0×	478 0.6×	810 1.3×	109	2.7k
Paula Marlton Australia	27	1.2k 0.6×	803 0.9×	988 1.2×	789 1.0×	1.1k 1.6×	137	3.1k
H. Kent Holland United States	22	2.1k 1.1×	1.0k 1.1×	921 1.2×	795 1.0×	268 0.4×	100	3.1k
Martin Wermke Germany	25	2.2k 1.1×	517 0.6×	1.2k 1.5×	885 1.2×	1.2k 1.9×	152	3.7k
Francesco Onida Italy	31	1.7k 0.9×	411 0.4×	643 0.8×	1.3k 1.6×	506 0.8×	118	3.0k
David S. Viswanatha United States	32	1.2k 0.6×	504 0.6×	1.1k 1.4×	966 1.3×	590 0.9×	133	3.6k
Yoshiaki Sonoda Japan	25	1.0k 0.5×	682 0.7×	431 0.5×	444 0.6×	718 1.1×	81	2.0k
Alexander Kiani Germany	25	935 0.5×	623 0.7×	1.1k 1.4×	394 0.5×	680 1.1×	78	2.7k
Christoph Walz Germany	25	792 0.4×	466 0.5×	375 0.5×	679 0.9×	650 1.0×	70	2.1k

Countries citing papers authored by Erkut Bahceci

Since Specialization

Citations

This map shows the geographic impact of Erkut Bahceci's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erkut Bahceci with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erkut Bahceci more than expected).

Fields of papers citing papers by Erkut Bahceci

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erkut Bahceci. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erkut Bahceci. The network helps show where Erkut Bahceci may publish in the future.

Co-authorship network of co-authors of Erkut Bahceci

This figure shows the co-authorship network connecting the top 25 collaborators of Erkut Bahceci. A scholar is included among the top collaborators of Erkut Bahceci based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erkut Bahceci. Erkut Bahceci is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Smith, Catherine C., Mark R. Litzow, Alexander E. Perl, et al.. (2021). Correction to: Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor. Clinical Pharmacokinetics. 60(9). 1251–1251. 1 indexed citations

Smith, Catherine C., Mark R. Litzow, Alexander E. Perl, et al.. (2020). Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor. Clinical Pharmacokinetics. 59(10). 1273–1290. 50 indexed citations

Ono, Akira, Haruyasu Murakami, Takashi Seto, et al.. (2020). Safety and Antitumor Activity of Repeated ASP3026 Administration in Japanese Patients with Solid Tumors: A Phase I Study. Drugs in R&D. 21(1). 65–78. 4 indexed citations

Esteve, Jordi, Rik Schots, Teresa Bernal, et al.. (2019). PS1065 OPEN‐LABEL STUDY OF GILTERITINIB, GILTERITINIB PLUS AZACITIDINE, OR AZACITIDINE ALONE IN NEWLY DIAGNOSED FLT3‐MUTATED AML PATIENTS INELIGIBLE FOR INTENSIVE CHEMOTHERAPY: RESULTS FROM THE SAFETY COHORT. HemaSphere. 3(S1). 482–482. 5 indexed citations

Smith, Catherine C., Mark J. Levis, Alexander E. Perl, et al.. (2019). Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial. Blood. 134(Supplement_1). 14–14. 17 indexed citations

Wang, Jie, Jing Li, Adisak Tantiworawit, et al.. (2018). A phase III randomized study of gilteritinib versus salvage chemotherapy in FLT3 mutation-positive subjects with relapsed or refractory acute myeloid leukemia. Annals of Oncology. 29. ix92–ix92. 2 indexed citations

Esteve, Jordi, Rik Schots, Teresa Bernal, et al.. (2018). Multicenter, Open-Label, 3-Arm Study of Gilteritinib, Gilteritinib Plus Azacitidine, or Azacitidine Alone in Newly Diagnosed FLT3 Mutated (FLT3mut+) Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Induction Chemotherapy: Findings from the Safety Cohort. Blood. 132(Supplement 1). 2736–2736. 45 indexed citations

Cortes, Jörge E., Jessica K. Altman, Ellen K. Ritchie, et al.. (2017). A phase II/III, multicenter, open-label, 3-arm study of gilteritinib, gilteritinib plus azacitidine, or azacitidine alone in the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia (AML) patients ineligible for intensive induction chemotherapy.. Journal of Clinical Oncology. 35(15_suppl). TPS7068–TPS7068. 8 indexed citations

Pratz, Keith W., Mohamad Cherry, Jessica K. Altman, et al.. (2017). Preliminary Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML). Blood. 130(Suppl_1). 722–722. 14 indexed citations

10.

Smith, Catherine C., Mark J. Levis, Mark R. Litzow, et al.. (2016). Pharmacokinetics and pharmacodynamics of gilteritinib in patients with relapsed or refractory acute myeloid leukemia.. Journal of Clinical Oncology. 34(15_suppl). 7026–7026. 5 indexed citations

11.

Li, Tianhong, Patricia LoRusso, Michael L. Maitland, et al.. (2016). First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors. Journal of Hematology & Oncology. 9(1). 23–23. 20 indexed citations

12.

Levis, Mark J., Alexander E. Perl, Jessica K. Altman, et al.. (2015). Results of a first-in-human, phase I/II trial of ASP2215, a selective, potent inhibitor of FLT3/Axl in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML).. Journal of Clinical Oncology. 33(15_suppl). 7003–7003. 30 indexed citations

13.

Maitland, Michael L., Sai‐Hong Ignatius Ou, Anthony W. Tolcher, et al.. (2014). Safety, activity, and pharmacokinetics of an oral anaplastic lymphoma kinase (ALK) inhibitor, ASP3026, observed in a “fast follower” phase 1 trial design.. Journal of Clinical Oncology. 32(15_suppl). 2624–2624. 18 indexed citations

14.

Saglio, Giuseppe, Jörge E. Cortes, CA Schiffer, et al.. (2010). Types of resistance to imatinib and other potential predictors of response to second-line dasatinib therapy.. Journal of Clinical Oncology. 28(15_suppl). 6569–6569. 2 indexed citations

15.

Shah, Neil P., Erkut Bahceci, Alexandre Lambert, Lynn Ploughman, & Jerald P. Radich. (2009). Resistance, Outcome and the Development of Mutations with Dasatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP).. Blood. 114(22). 1122–1122. 5 indexed citations

16.

Takahashi, Yoshiyuki, Abdul Tawab, Roger Kurlander, et al.. (2005). AMD3100 Mobilized Apheresis Products Are Rich in T-Cells That Do Not Undergo a Th-2 Type Cytokine Polarization: Implications for Allografting.. Blood. 106(11). 296–296. 6 indexed citations

17.

Solomon, Scott R., Thuong Hien Tran, Sheila Donnelly, et al.. (2002). Optimized clinical-scale culture conditions for ex vivo selective depletion of host-reactive donor lymphocytes: a strategy for GvHD prophylaxis in allogeneic PBSC transplantation. Cytotherapy. 4(5). 395–406. 51 indexed citations

18.

Nakamura, Ryotaro, Erkut Bahceci, Elizabeth J. Read, et al.. (2001). Transplant dose of CD34⁺ and CD3⁺ cells predicts outcome in patients with haematological malignancies undergoing T cell‐depleted peripheral blood stem cell transplants with delayed donor lymphocyte add‐back. British Journal of Haematology. 115(1). 95–104. 53 indexed citations

19.

Childs, Richard, Diane E. Epperson, Erkut Bahceci, Emmanuel Clave, & John Barrett. (1999). Molecular remission of chronic myeloid leukaemia following a non‐myeloablative allogeneic peripheral blood stem cell transplant: in vivo and in vitro evidence for a graft‐versus‐leukaemia effect. British Journal of Haematology. 107(2). 396–400. 34 indexed citations

20.

Childs, Richard, Emmanuel Clave, Nathalie Contentin, et al.. (1999). Engraftment Kinetics After Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation: Full Donor T-Cell Chimerism Precedes Alloimmune Responses. Blood. 94(9). 3234–3241. 448 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact